Why I'm Selling Sellas Life Sciences Ahead Of The REGAL Reveal
Source: SeekingAlpha
2026-01-19 08:07:13 ET
Sellas Life Sciences’ stock ( SLS ) has risen >300% in the past year ahead of Phase 3 data for its peptide immunotherapy, galinpepimut-S (GPS), in patients with AML in second remission....
Read the full article on Seeking Alpha
For further details see:
Why I'm Selling Sellas Life Sciences Ahead Of The REGAL Reveal
SELLAS Life Sciences Group Inc.
NASDAQ: SLS
SLS Trading
20.38% G/L:
$6.97 Last:
7,820,479 Volume:
$6.48 Open:
SLS Latest News
May 12, 2026 04:05:00 pm
SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update
March 19, 2026 04:05:00 pm
SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update
SLS Stock Data
$535,597,063
140,448,048
1.12%
50
N/A
Biotechnology & Life Sciences
Healthcare
US
New York
